Information on sugar and sugar substitutes, lasers and photodynamic therapy, inflammation, World Diabetes Day

Happy Fall to everyone. As the days get shorter, and the weather becomes cooler, we say good-bye to the dog days of summer and look for to the holidays ahead and the New Year. This issue features much- needed information on sugar and sugar substitutes, as well as lasers photo dynamic therapy, inflammation, and World Diabetes Day. Thanks to Karen and Dagmar for their contributions. Common to both diabetes and excessive consumption of sugar is obesity. The Food and Drug Administration (FDA) approved a drug for overweight/obesity, and it is lorcaserin HCl (Belviq) (Arena Pharmaceuticals).(1,2) It has been approved as an addition to a reduced-calorie diet and exercise regimen for chronic weight management. It is approved for use in adults with a body mass index (BMI) of 30 or greater (obese) or adults with a BMI of 27 or greater (overweight) and who have at least one weight-related condition such as hypertension, type 2 diabetes, or dyslipidemia. The medication works by activating the serotonin 2C receptor in the brain, which is thought to help a person eat less and feel full after eating smaller amounts of food. The safety and efficacy of lorcaserin were evaluated in three randomized, placebo-controlled trials that included nearly 8,000 obese and overweight patients, with and without type 2 diabetes, treated for 52 to 104 weeks. All participants received lifestyle modification that included a reduced-calorie diet and exercise counseling. Compared with placebo, treatment with lorcaserin for up to 1 year was associated with an average weight loss of 3% to 3.7%. The most common adverse reactions of lorcaserin in nondiabetic patients are headache, dizziness, fatigue, nausea, dry mouth, and constipation. In patients with diabetes, hypoglycemia, headache, back pain, cough, and fatigue were most common.

As well, there are new resources available that focus on oral health of pregnant women. The National Maternal and Child Oral Health Policy Center (NMCOHPC), in collaboration with the Association of Maternal and Child Health Programs (AMCHP), Association of State and Territorial Dental Directors (ASTDD), March of Dimes (MOD), and Washington Dental Service (WDS) Foundation, has released a brief that focuses on the oral health of pregnant women and young children.(3) The brief is designed to provide state policymakers a brief review of the research and evidence on dental care during the perinatal period, according to the center. It identifies current state guidelines that have been developed, reviews liability issues for dentists and medical providers, and outlines current state policy options to support the oral health of pregnant women and young children. It is available for download.(4)

In associated news, the National Maternal and Child Oral Health Resource Center has issued "Oral Health Care During Pregnancy," a national consensus statement and summary of an expert work group meeting. This document is intended to help professionals working in states and communities plan, develop, and implement programs to help ensure that pregnant women receive optimal oral health services. It was developed with support from the Maternal and Child Heath Bureau of the Health Resources and Services Administration.(5) There is also a new Centers for Disease Control and Prevention (CDC) Report on the Prevalence of Periodontitis in Adults in the United States.(6)